 |
|
|
| |
Prevalence and risk factors of preexisting TAMs in clinical trial participants and sustained viral suppression after switching to bictegravir/emtricitabine/tenofovir alafenamide
|
| |
| |
18th EACS 2021 Oct 27-30
K. Andreatta1, R. Acosta1, M.L. D'Antoni1, H. Liu1, S. Chang1, R. Martin1, S. Collins1, H. Martin1, K.L. White1
1Gilead Sciences, Inc., Foster City, United State
|
| |
|
|
|
|
|
